These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7855253)

  • 1. Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias.
    Bays HE; Dujovne CA
    Prog Drug Res; 1994; 43():9-41. PubMed ID: 7855253
    [No Abstract]   [Full Text] [Related]  

  • 2. Getting cardiologists interested in lipids.
    Roberts WC
    Am J Cardiol; 1993 Sep; 72(9):744-5. PubMed ID: 8249858
    [No Abstract]   [Full Text] [Related]  

  • 3. Economics of lipid lowering with HMG CoA reductase inhibitors.
    Illingworth DR
    Clin Cardiol; 1995 Jun; 18(6):295, 363. PubMed ID: 7664501
    [No Abstract]   [Full Text] [Related]  

  • 4. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Comparative economic data regarding lipid-lowering drugs.
    Schwartz JS
    Am Heart J; 1999 May; 137(5):S97-104. PubMed ID: 10220608
    [No Abstract]   [Full Text] [Related]  

  • 5. [Lipid therapy. Prevention of arteriosclerotic cardiovascular diseases].
    Windler E
    Internist (Berl); 2001 Jan; 42(1):92-110. PubMed ID: 11271625
    [No Abstract]   [Full Text] [Related]  

  • 6. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective.
    Kessler JM
    Am Heart J; 1999 May; 137(5):S111-4. PubMed ID: 10220610
    [No Abstract]   [Full Text] [Related]  

  • 7. How drug prices are set: an example from the perspective of a social security association.
    Eichler HG; Bucsics A; Wieninger P
    Clin Pharmacol Ther; 2002 Jul; 72(1):101-3. PubMed ID: 12152009
    [No Abstract]   [Full Text] [Related]  

  • 8. [HMG-CoA reductase inhibitors].
    Yamamoto A
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():578-86. PubMed ID: 11347135
    [No Abstract]   [Full Text] [Related]  

  • 9. [Impact for the control of cholesterolemia: diet versus drugs].
    Rev Assoc Med Bras (1992); 2003; 49(2):117. PubMed ID: 12886369
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug intervention trials in dyslipidemia: the past and the future.
    Dujovne CA
    Clin Cardiol; 1991 Feb; 14(2 Suppl 1):I48-52. PubMed ID: 2044259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hypercholesterolemia in women: equality, effectiveness, and extrapolation of evidence.
    Pearson TA; Myerson M
    JAMA; 1997 Apr 23-30; 277(16):1320-1. PubMed ID: 9109473
    [No Abstract]   [Full Text] [Related]  

  • 12. [Current approaches to the diagnosis and correction of atherogenic dyslipoproteinemia].
    Oganov RG; Perova NV
    Kardiologiia; 1989 Oct; 29(10):15-22. PubMed ID: 2615152
    [No Abstract]   [Full Text] [Related]  

  • 13. The case for aggressive lipid regulation.
    Gotto AM
    Hosp Pract (1995); 1997 Feb; 32(2):145-9, 155-6. PubMed ID: 9040426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia.
    Stefanutti C; Morozzi C; Di Giacomo S
    Curr Med Chem; 2012; 19(28):4861-8. PubMed ID: 22963620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of high blood cholesterol in patients with coronary heart disease].
    Nagai Y; Yamashita S
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():675-81. PubMed ID: 12735049
    [No Abstract]   [Full Text] [Related]  

  • 16. [Enduracin--a nicotinic acid preparation in the treatment of hypercholesterolemia].
    Kardiologiia; 1993; 33(11):67-80. PubMed ID: 8145429
    [No Abstract]   [Full Text] [Related]  

  • 17. Implementing new guidelines in the management of blood cholesterol.
    Boyden TF; Brook RD; Jackson E; Rubenfire M; Eagle K
    Am J Med; 2014 Aug; 127(8):705-6. PubMed ID: 24569024
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical evaluation of MK-185: a new hypolipidemic drug.
    Sirtori C; Hurwitz A; Sabih K; Azarnoff D
    Lipids; 1972 Feb; 7(2):96-9. PubMed ID: 4551950
    [No Abstract]   [Full Text] [Related]  

  • 19. The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease.
    Eidelman RS; Lamas GA; Hennekens CH
    Arch Intern Med; 2002 Oct; 162(18):2033-6. PubMed ID: 12374510
    [No Abstract]   [Full Text] [Related]  

  • 20. Are the new Lipid Management Guidelines good for Australia's health?
    Jackson RT
    Med J Aust; 2001 Nov; 175(9):452-3. PubMed ID: 11758069
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.